EDGAR·FLOW

Enveric Biosciences, Inc. — Form 8-K

Filed November 13, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
Enveric Biosciences reported Q3 2026 net loss of $2.5M ($0.57 per share) versus $3.4M in Q3 2025, with cash-on-hand of $5.6M as of September 30, 2026. The company completed IND-enabling ADMET studies for lead candidate EB-003 (non-hallucinogenic mescaline derivative) showing favorable absorption and reduced drug-drug interactions; preclinical qEEG study demonstrated brain penetration with activity pattern distinct from DMT; and secured U.S. patent allowance for EVM401 Series. IND submission planned with first-in-human Phase 1 trial to follow.
Why this rating

EB-003 advancement materially de-risks lead program; $2.5M quarterly burn against $5.6M cash gives ~9 months runway—critical near-term milestone dependency. Positive preclinical data supports regulatory path but not yet clinical proof.

Tradability signal
NO TRADE

No trade: positive news with only -0.3% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.04% over 4 hrs, n=508). (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$1.51 ▲ 0.33%
at our read · unknown
$1.51
+10 min · unknown
$1.54 ▲ 1.99%
+30 min · unknown
$1.51 ▲ 0.00%
+1 hr · unknown
$1.51 ▲ 0.00%
+4 hrs · unknown
$1.46 ▼ 3.31%

The stock had already moved -0.33% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ ENVB · stock on Yahoo Finance ↗

See more from November 13, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.